This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
2026-05-17 14:42:28 ET
HighVista Strategies sold 69,092 shares of Structure Therapeutics (NASDAQ:GPCR) in the first quarter, an estimated $4.73 million trade based on quarterly average pricing, per the May 15, 2026 SEC filing.
According to an SEC filing dated May 15, 2026, HighVista Strategies reduced its holding in Structure Therapeutics by 69,092 shares during the first quarter. The estimated transaction value was $4.73 million, calculated using the average closing price for the quarter. The position’s quarter-end value decreased by $7.45 million, a figure that incorporates both the share sale and market price fluctuations.
Structure Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative oral small molecule therapeutics for chronic diseases with significant unmet need. The company's strategy leverages expertise in GPCR biology to advance a pipeline of differentiated oral therapeutics for chronic diseases. With a focus on metabolic and pulmonary indications, Structure Therapeutics seeks to establish a competitive edge through proprietary drug design and a robust clinical development program.
NASDAQ: GPCR
GPCR Trading
-2.93% G/L:
$38.05 Last:
159,868 Volume:
$38.71 Open:
